BioCentury
ARTICLE | Clinical News

Tecentriq meets PFS endpoint in first-line TNBC

July 6, 2018 4:44 PM UTC

Genentech Inc. said Tecentriq atezolizumab met the co-primary endpoint of improving progression-free survival (PFS) in the Phase III IMpassion130 trial as first-line treatment of triple-negative breast cancer (TNBC). The Roche (SIX:ROG; OTCQX:RHHBY) unit said the data are the first positive Phase III readout for an immunotherapy in the indication.

The double-blind, international IMpassion130 trial enrolled 902 patients with locally advanced or metastatic TNBC who have not received prior systemic therapy for metastatic breast cancer and compared Tecentriq plus Abraxane nab-paclitaxel vs. placebo plus Abraxane. Genentech said Tecentriq plus Abraxane significantly improved PFS in both the intent-to-treat (ITT) and PD-L1-positive populations vs. placebo plus Abraxane...